XORTX Therapeutics Inc. SEC filings XRTX

XORTX Therapeutics Inc. has 291 filings in SEC EDGAR's recent list, going back to Jan 25, 2018. Its latest annual report, Form 20-F, was filed on Mar 20, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 8, 2026. The company's fiscal year ends on December 31.

XORTX Therapeutics Inc. SEC filings
Form Description Filed Period
20-F Annual report (foreign issuer) Mar 20, 2026 Dec 31, 2025
20-F Annual report (foreign issuer) May 12, 2025 Dec 31, 2024
20-F Annual report (foreign issuer) May 10, 2024 Dec 31, 2023
20-F Annual report (foreign issuer) Apr 28, 2023 Dec 31, 2022
20-F/A Amended annual report (foreign issuer) Jan 27, 2023 Dec 31, 2021
20-F Annual report (foreign issuer) May 3, 2022 Dec 31, 2021

Showing 6 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
XRTX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
British Columbia, Canada
Headquarters
Vancouver, British Columbia, Canada
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1729214

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.